Swedish Orphan Biovitrum

Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
Catalysts ahead for the smaller players
Catalysts ahead for the smaller players
EP Vantage
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
Flag link:
Systemic lupus erythematosus: major drug trials to watch in 2022 and 2023
Systemic lupus erythematosus: major drug trials to watch in 2022 and 2023
Clinical Trials Arena
clinical trials
systemic lupus erythematosus
AbbVie
ABBV-509
Eli Lilly
LY3471851
Merck KGaA
M5049
Swedish Orphan Biovitrum
emapalumab
Flag link:
Biopharma M&A: deal-depressed third quarter leaves nowhere to hide
Biopharma M&A: deal-depressed third quarter leaves nowhere to hide
EP Vantage
M&A
Lundbeck
Alder Biopharmaceuticals
Gilead Sciences
Galapagos
Vertex Pharmaceuticals
Semma
Swedish Orphan Biovitrum
Dova Pharmaceuticals
Novartis
IFM
Flag link:
Dova Pharma's bet on Eisai castoff spells gold as Sobi spends millions to acquire it
Dova Pharma's bet on Eisai castoff spells gold as Sobi spends millions to acquire it
Endpoints
Dova Pharmaceuticals
Eisai
Swedish Orphan Biovitrum
M&A
Flag link:
Swedish Orphan Plunges After Talks End on Potential Takeover
Swedish Orphan Plunges After Talks End on Potential Takeover
Bloomberg
M&A
Swedish Orphan Biovitrum
Sobi
Flag link:
Pfizer emerges as mystery bidder for rare disease firm Swedish Orphan
Pfizer emerges as mystery bidder for rare disease firm Swedish Orphan
BioPharma Dive
Pfizer
M&A
Swedish Orphan Biovitrum
Sobi
Flag link:
Biogen partner Sobi and its Boston-based CEO field a takeover bid
Biogen partner Sobi and its Boston-based CEO field a takeover bid
Fierce Biotech
Sobi
Swedish Orphan Biovitrum
Biogen
M&A
Flag link:
Swedish Orphan Said to Be Open to Sale Amid Boom in Drug Deals
Swedish Orphan Said to Be Open to Sale Amid Boom in Drug Deals
Bloomberg
Swedish Orphan Biovitrum
M&A
Pfizer
Biogen
Flag link:
Biogen, Sobi pledge hemophilia drug donation in developing world
Biogen, Sobi pledge hemophilia drug donation in developing world
Yahoo/Reuters
Biogen Idec
hemophilia
Swedish Orphan Biovitrum
Flag link: